Nucleome Therapeutics nominates first preclinical development candidate
PR Newswire —
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases Evolution of Nucleome's non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need OXFORD,...